focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.15
Bid: 39.15
Ask: 39.65
Change: 0.25 (0.64%)
Spread: 0.50 (1.277%)
Open: 39.05
High: 39.35
Low: 38.85
Prev. Close: 38.90
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Initial Launch of CSD500 in MENA

5 Jan 2017 07:00

RNS Number : 3809T
Futura Medical PLC
05 January 2017
 

For immediate release 5 January 2017

  

 

Futura Medical plc

("Futura" or the "Company")

Initial Launch of CSD500 in MENA

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that CSD500, its novel erectogenic condom, has launched in Saudi Arabia by Kabey Pharmaceuticals ("Kabey"), the Company's distribution partner for key territories in the Middle East and North Africa ("MENA"). Kabey anticipates further launches within MENA during 2017.

The launch of the product, under the brand name Futura Max Manex® Super, follows positive feedback from urologists after their trial use of the product. In addition to raising further medical awareness of the product with urologists, Kabey will now implement a direct retail marketing campaign. The marketing plans do not include online sales as, in the MENA region, this is not a popular route to market for such products.

James Barder, Futura's Chief Executive, commented: "We are delighted that our novel erectogenic condom, CSD500, has now been launched in Saudi Arabia by our commercial partner in the Middle East and North Africa, Kabey Pharmaceuticals. The product launch follows positive feedback from urologists after their trial use of CSD500.

"Kabey is well-established with a strong presence in the MENA region. It will now implement a direct retail marketing campaign which we are confident will be successful for CSD500. We look forward to updating the market regarding further launches of CSD500 within MENA during 2017."

This announcement contains inside information.

For further information please contact:

Futura Medical plc

 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

Tel:+44 (0) 20 7496 3000

 

 

For media enquiries please contact:

 

Buchanan

 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDBIMMTMBAMTTR
Date   Source Headline
9th Jun 20213:58 pmRNSTR-1: Notification of major holdings
3rd Jun 20214:19 pmRNSTR-1: Notification of major holdings
3rd Jun 202111:00 amRNSNotice of AGM and Annual Report
2nd Jun 202112:50 pmRNSResult of General Meeting & Total Voting Rights
1st Jun 20217:00 amRNSBlock Listing Six Monthly Return
17th May 20213:08 pmRNSPosting of Circular and Notice of General Meeting
17th May 20217:00 amRNSResult of Placing and Retail Offer
14th May 20214:41 pmRNSSecond Price Monitoring Extn
14th May 20214:35 pmRNSPrice Monitoring Extension
14th May 20214:31 pmRNSRetail Offer by PrimaryBid
14th May 20214:30 pmRNSProposed Placing to raise £10 mil & Retail Offer
4th May 20215:18 pmRNSTR-1: Notification of major holdings
4th May 20215:15 pmRNSTR-1: Notification of major holdings
4th May 20217:00 amRNSTotal Voting Rights
30th Apr 20217:00 amRNSFutura Receives Approval from EU Notified Body
28th Apr 20212:57 pmRNSTR-1: Notification of major holdings
28th Apr 20219:31 amRNSTR-1: Notification of major holdings
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.